Biotechnology Management
Kellogg School of Management
  Home
  About Biotech at   Kellogg
  Faculty & Research
Faculty
Case Collection
Kellogg on Biotech
Science Bootcamp
Medical Innovation
  Executive Education
  News Archive
  FAQ
  Contact
 
 
  Index
  Search
  Internal Site
  Northwestern University
 
   

Kellogg on Biotech

Analysis of the Risks Embedded in Asymmetrical Alliances in the Pharmaceutical Industry

John Hughes KSM '05, Edna Lazar KSM '05, and Guilherme Maradei KSM '05

Asymmetrical alliances are particularly interesting due to the imbalance of power between the partners, sometimes leading to the acquisition of the smaller firm by its larger partner. The pharmaceutical sector has a natural tendency for deals between very large and very small companies. In this fast-paced, technology-driven industry, small biotechnology companies have proliferated rapidly in the last decade, leveraging the fact that research for new biotechnology-based drugs does not require large infrastructure. Recently thebiotech firms have been responsible for a large portion of the research and development in the industry, attracting the interest of the large pharmaceutical companies. Through the so-called “pharma-biotech” alliances, pharmaceutical giants have found a way to supplement their drug development pipelines, whereas small biotech firms have been able to multiply the potential of their discoveries, leveraging the pharmaceutical companies’ regulatory experience and marketing strength.

Nevertheless, the differences between large pharma companies and smaller biotech firms pose significant threats to the success of deals.

This paper analyzes the dynamics of asymmetrical alliances in the health industry sector, where deals between large pharmaceutical companies and small biotechnology firms have become extremely common.

©2007 Kellogg School of Management, Northwestern University